New LDL cholesterol target ahead?

03/4/2013 | Nature (free content)

For the first time in a decade, the U.S. National Heart, Lung and Blood Institute is expected to reconsider its clinical guidelines for LDL cholesterol. Statins have been shown to lower the risk of cardiovascular events, but it has not been proven that reducing LDL with other pharmaceuticals has an impact, some cardiologists say. "We can't just assume that modifying the risk factor is modifying risk," says Harlan Krumholz of Yale University.

View Full Article in:

Nature (free content)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park